TriMod Therapeutics Ltd is an early stage biotechnology company whose primary R&D focus is dedicated to developing novel platform technologies to treat cancer and autoimmune diseases.
TriMod was founded on ground-breaking technology originating from the laboratory of Prof. Kingston Mills at Trinity College Dublin. TriMoVav is a pre-clinically validated technology that has the potential to revolutionise the treatment of cancer. Using the patients' own immune system, this innovative technology will specifically target tumours without the need for debilitating chemotherapy. The therapeutic potential is broad and has the ability to tackle several tumour types.